Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart
(18 July 2012)
Read the full announcement in PDF format

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 8 November 2012 to discuss the New Drug Applications (NDA) for the ultra-long-acting insulin degludec and insulin degludec/insulin aspart.

Further information:
Media:  Investors:
Mike Rulis  Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573  Tel: (+45) 4442 4303
[email protected]  [email protected]

Frank Daniel Mersebach
Tel: (+45) 4442 0604
[email protected]

Lars Borup Jacobsen
Tel: (+45) 3075 3479
[email protected]

In North America: 
Ken Inchausti  Jannick Lindegaard
Tel: (+1) 609 514 8316  Tel: (+1) 609 786 4575
[email protected]  [email protected]

Company Announcement No 46 / 2012
 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.